Jay Klievink

942 total citations
15 papers, 306 citations indexed

About

Jay Klievink is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Jay Klievink has authored 15 papers receiving a total of 306 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Immunology, 8 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Jay Klievink's work include Immune Cell Function and Interaction (11 papers), CAR-T cell therapy research (7 papers) and Acute Myeloid Leukemia Research (3 papers). Jay Klievink is often cited by papers focused on Immune Cell Function and Interaction (11 papers), CAR-T cell therapy research (7 papers) and Acute Myeloid Leukemia Research (3 papers). Jay Klievink collaborates with scholars based in Finland, United States and Norway. Jay Klievink's co-authors include Satu Mustjoki, Olli Dufva, Aleksandr Ianevski, Tero Aittokallio, Noora Ottman, Ioannis Kostopoulos, Jan Knol, Steven Aalvink, Matti Kankainen and Khalid Saeed and has published in prestigious journals such as Blood, Scientific Reports and Science Advances.

In The Last Decade

Jay Klievink

12 papers receiving 303 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jay Klievink Finland	4	164	134	76	68	57	15	306
Bradley W. Lash United States	8	161 1.0×	215 1.6×	38 0.5×	8 0.1×	28 0.5×	19	384
Lauge Kellermann Denmark	7	72 0.4×	109 0.8×	82 1.1×	84 1.2×	23 0.4×	8	284
Meike Kespohl Germany	9	281 1.7×	118 0.9×	171 2.3×	38 0.6×	11 0.2×	16	470
Yingfei Li China	12	247 1.5×	103 0.8×	44 0.6×	43 0.6×	11 0.2×	21	408
Mariam Al-Omari Jordan	6	103 0.6×	56 0.4×	55 0.7×	19 0.3×	10 0.2×	15	315
Wesley Huang United States	6	187 1.1×	59 0.4×	25 0.3×	21 0.3×	21 0.4×	14	274
Xiaochen Xiong China	4	185 1.1×	62 0.5×	53 0.7×	50 0.7×	17 0.3×	4	291
Emily Lowe United States	8	143 0.9×	88 0.7×	171 2.3×	61 0.9×	4 0.1×	13	362
Alfred A. Chan United States	7	173 1.1×	135 1.0×	95 1.3×	21 0.3×	15 0.3×	19	338
Elena Ferrer-Picón Spain	3	136 0.8×	93 0.7×	64 0.8×	123 1.8×	22 0.4×	4	296

Countries citing papers authored by Jay Klievink

Since Specialization

Citations

This map shows the geographic impact of Jay Klievink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay Klievink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay Klievink more than expected).

Fields of papers citing papers by Jay Klievink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay Klievink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay Klievink. The network helps show where Jay Klievink may publish in the future.

Co-authorship network of co-authors of Jay Klievink

This figure shows the co-authorship network connecting the top 25 collaborators of Jay Klievink. A scholar is included among the top collaborators of Jay Klievink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay Klievink. Jay Klievink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Jokinen, Emmi, Essi Laajala, Shady Adnan Awad, et al.. (2025). High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia. Blood. 145(15). 1670–1686. 2 indexed citations

Jokinen, Emmi, Jani Huuhtanen, Jay Klievink, et al.. (2025). Predicting antigen-specific T-cell immunity against Wilms tumor 1 in hematologic cancer. Leukemia. 39(11). 2767–2778.

Lahtinen, Laura, Mikko Räsänen, Karita Peltonen, et al.. (2024). Ex vivo modeling of precision immuno-oncology responses in lung cancer. Science Advances. 10(44). eadq6830–eadq6830. 2 indexed citations

Awad, Shady Adnan, Olli Dufva, Jay Klievink, et al.. (2024). Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia. Cell Reports Medicine. 5(5). 101521–101521. 9 indexed citations

Klievink, Jay, Hanna Lähteenmäki, Emmi Jokinen, et al.. (2024). Bone Marrow Stromal Cells Hamper Leukemia Cell Induced NK Cell Activation and Cytotoxicity. Blood. 144(Supplement 1). 4814–4814. 2 indexed citations

Huuhtanen, Jani, Shady Adnan Awad, Olli Dufva, et al.. (2023). Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation. Leukemia. 38(1). 109–125. 17 indexed citations

Dufva, Olli, Emmi Jokinen, Hanna Lähteenmäki, et al.. (2023). Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells. Blood. 142(Supplement 1). 66–66.

Jokinen, Emmi, Essi Laajala, Aleksandr Ianevski, et al.. (2023). High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers. Blood. 142(Supplement 1). 3634–3634.

Huuhtanen, Jani, Oscar Brück, Karita Peltonen, et al.. (2021). Single-Cell Characterization of the Immune and Leukemic Cells Following Anti-TIM3 and Hypomethylating Agent Combination Therapy in Patients with AML or MDS. Blood. 138(Supplement 1). 801–801. 1 indexed citations

10.

Gandolfi, Sara, Olli Dufva, Jani Huuhtanen, et al.. (2021). Functional Genomic Landscape of Natural Killer Cell Evasion in Multiple Myeloma. Blood. 138(Supplement 1). 732–732. 2 indexed citations

11.

Gandolfi, Sara, Olli Dufva, Jani Huuhtanen, et al.. (2021). OAB-019: CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S12–S13. 1 indexed citations

12.

Kostopoulos, Ioannis, Janneke Elzinga, Noora Ottman, et al.. (2020). Akkermansia muciniphila uses human milk oligosaccharides to thrive in the early life conditions in vitro. Scientific Reports. 10(1). 14330–14330. 109 indexed citations

13.

Huuhtanen, Jani, Andreas Burchert, Tiina Kasanen, et al.. (2020). Single-Cell Roadmap of Immune Cell Response in Chronic Myeloid Leukemia. Blood. 136(Supplement 1). 4–5. 1 indexed citations

14.

Dufva, Olli, Pilvi Maliniemi, Aleksandr Ianevski, et al.. (2019). Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood. 135(9). 597–609. 157 indexed citations

15.

Dufva, Olli, Khalid Saeed, Sara Gandolfi, et al.. (2019). CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers. Blood. 134(Supplement_1). 3597–3597. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact